Drug Profile
LY 3009120
Alternative Names: DP-4978; LSN 3074753; LY-3009120; Pan-Raf Inhibitor - Deciphera/Eli LillyLatest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Deciphera Pharmaceuticals
- Developer Deciphera Pharmaceuticals; Eli Lilly and Company
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto oncogene protein b raf inhibitors; Proto oncogene proteins c raf inhibitors; Ras signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in USA (PO, Capsule)
- 27 Dec 2018 Chemical structure information added
- 03 Dec 2018 Eli Lilly terminates a phase I trial in Cancer (Late-stage disease, Second-line therapy or greater) in USA based on the lack of sufficient clinical efficacy observed (PO) (NCT02014116)